B · Normal
[Johnson & Johnson intends to acquire Ollin Biosciences for US$2.2 billion in cash, with additional milestone payments of up to US$1.125 billion] On November 16, Johnson & Johnson announced that it has reached a final agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company, for a transaction consideration of US$2.2 billion in cash, plus regulatory and commercial milestone payments of up to approximately US$1.125 billion. The transaction is expected to be completed before the end of 2026, subject to obtaining relevant regulatory approvals and satisfying customary closing conditions. Johnson & Johnson will also reach an independent development funding agreement with Blackstone Life Sciences to support the Phase III clinical development of related drugs.
Global market intelligence 🕐 2026-11-16 21:04

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet